Cipla launches “Covi-G” for COVID-19 rapid antibody detection Kumar Jeetendra | November 18, 2020 Mumbai, November 18, 2020: Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as “Cipla”) today announced that it signed a licensing agreement with a Belgium-based firm, Multi G for the distribution of their COVID-19 Rapid Antibody test kit, across most Emerging markets and Europe. This licencing agreement is part of Cipla’s efforts …
Dose-escalation study to evaluate safety, biological and early clinical effect of CALY-002 in healthy volunteers and patients with Celiac Disease and Eosinophilic Esophagitis Kumar Jeetendra | November 16, 2020 AMSTERDAM, The Netherlands, November 16, 2020 Calypso Biotech, a company developing Interleukin-15-targeted biologics, today announced completion of dosing of first cohort of healthy subjects in the first Phase 1 clinical trial of CALY-002, a novel humanized monoclonal antibody neutralizing IL-15. “CALY-002 is the lead program of our differentiated pipeline of IL-15-targeting biologics, that we plan …
Lead Pharma Enters into a Research Collaboration and License Agreement with Roche Kumar Jeetendra | November 16, 2020 OSS, The Netherlands, November 16, 2020 Lead Pharma, a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated diseases and cancer, today announced that it has entered into a collaboration and license agreement with Roche to develop oral small molecules to treat a broad range of immune mediated diseases. …
Johnson and Johnson, US government extend settlement to help next phase of COVID-19 immunization R&D Kumar Jeetendra | November 15, 2020 Johnson & Johnson and the US Department of Health and Human Services have expanded an agreement to support the next phase of COVID-19 vaccine candidate research and development, the company said on Saturday. Under the agreement the company will commit approximately $604 million and the HHS Department’s Biomedical Advanced Research and Development Authority will commit …
Pill Connect secures £0.5m to take electronic smart pill bottle that monitors patient adherence to commercial launch Kumar Jeetendra | November 14, 2020 Pill Connect, formerly known as Elucid mHealth, has completed a £510,000 funding round with the support of the serial entrepreneur Jonathan Milner, Catapult Ventures and Shallcross Partners. The capital raised will enable Pill Connect to complete development of the design, electronics and software for submission to the regulatory authorities in both Europe and the US …
Lupin, Concord Biotech get USFDA gesture for generic immunosuppressant cases Kumar Jeetendra | November 12, 2020 New Delhi, Nov 12 (PTI) Drug firm Lupin on Thursday stated that in alliance with Concord Biotech, it has obtained acceptance from the US health regulator to market generic immunosuppressant Tacrolimus capsules used in the Western industry. In cooperation with Concord Biotech, the business has obtained approval from the United States Food and Drug Administration …
Glenmark Pharma gets USFDA gesture for Tacrolimus capsules Kumar Jeetendra | November 11, 2020 Tacrolimus capsule is an immunosuppressant and can be employed for preventing organ rejection in certain patients after kidney, liver, or heart transplant. Glenmark Pharmaceuticals Inc, USA, has been granted final approval by the United States Food and Drug Administration (USFDA) for Tacrolimus Capsules USP in the strengths of 0.5 mg, 1 mg and 5 mg, …
Repositive expands global cancer model network with CRO from Finland Kumar Jeetendra | November 10, 2020 CAMBRIDGE, UK – (November 10, 2020) – Life Science Newswire – Repositive, the world’s largest directory of preclinical cancer models, has expanded its global network of contract research organisation (CRO) partners with the addition of Pharmatest, a CRO providing clinically predictive preclinical efficacy services for oncology and skeletal diseases. Pharmatest brings to the partnership more …
BioNTech Expects immunisation effect of COVID-19 vaccine will last at least a year Kumar Jeetendra | November 9, 2020 BioNTech’s co-founder and chief executive said that he was hopeful that the protective effect of its experimental COVID-19 vaccine, co-developed with Pfizer, would endure for at least a year. Both companies earlier on Monday became the primary drugmakers to launch successful trial statistics, stating their vaccine was demonstrated to be 90 percent successful, a major …
AstraZeneca expects COVID-19 immunization information this year Kumar Jeetendra | November 5, 2020 AstraZeneca, the British drugmaker working on one of the world’s leading COVID-19 vaccine candidates, conquer third-quarter sales estimates on Thursday and reiterated it expects data from late-stage trials of the vaccine later this year. The business has taken on the development of Oxford University’s potential COVID-19 vaccine, scoring billions in funding and signing multiple prices …
Lincoln Pharmaceuticals Ltd reports 16.70% rise in the Standalone Net Profit at Rs. 35.19 crore in H1 FY21 Kumar Jeetendra | November 3, 2020 November 03, 2020: Lincoln Pharmaceuticals Limited, one of India’s leading healthcare companies has reported net profit of Rs. 35.19 crore for the H1 FY21 ended September 2020 as against net profit of Rs. 30.15 crore in the corresponding period last year, growth of 16.70%. Net revenue for the half year ended September 2020 reported at …
Zydus Cadila finishes stage 2 preliminary, to submit information in November Kumar Jeetendra | November 3, 2020 Cadila Healthcare (Zydus Cadila) said it has completed enrolment and dosing of 1,000 volunteers in phase-2 clinical trials of its possible Covid-19 vaccine, ZyCoV-D, and plans to submit the data to the Drug Controller General of India (DCGI) this past month. “At present the immunogenicity evaluation is going on,” said Sharvil Patel, Managing Director of …
